Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1b and childhood multiple sclerosis.

A B Adams1, W R Tyor, K R Holden

  • 1College of Medicine, Department of Neurology, Medical University of South Carolina, Charleston, USA.

Pediatric Neurology
|July 31, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Increased Pretransplant Frequency of CD28<sup>+</sup> CD4<sup>+</sup> T<sub>EM</sub> Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Belatacept-Resistant Rejection Is Associated With CD28<sup>+</sup> Memory CD8 T Cells.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

First-Year Waitlist Hospitalization and Subsequent Waitlist and Transplant Outcome.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Long-term interferon beta-1b treatment led to significant clinical improvement in a pediatric patient with relapsing-remitting multiple sclerosis (RRMS). This positive outcome occurred despite the development of neutralizing antibodies to the therapy.

Area of Science:

  • Neurology
  • Immunology
  • Pediatric Medicine

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Relapsing-remitting MS (RRMS) is the most common form, characterized by distinct attacks and remissions.
  • Interferon beta-1b is an established disease-modifying therapy for MS.

Observation:

  • A 7-year-old male with RRMS underwent long-term treatment with interferon beta-1b.
  • The patient developed high titers of neutralizing antibodies against interferon beta-1b during treatment.

Findings:

  • Despite the presence of neutralizing antibodies, the patient exhibited dramatic clinical improvement over 32 months.
  • No relapses were observed during the documented treatment period.

Related Experiment Videos

  • The therapeutic benefits of interferon beta-1b were maintained long-term.

    • Implications:

    • Interferon beta-1b may remain effective in some patients even after antibody development.
    • This case highlights the potential for sustained clinical benefit in pediatric MS patients.
    • Further research is warranted to understand the mechanisms underlying treatment response in the presence of antibodies.